Immunological mechanistic action of intravenous BCG-mediated protection against tuberculosis Authors: Sangwon Choi, Jiyun Park, Jung Joo Hong, Sung Jae Shin, Ju Mi Lee Published: 2026 ABSTRACT AbstractThe Bacillus Calmette-Guérin (BCG) vaccine, the only licensed vaccine against tuberculosis (TB), has played a crucial role in mitigating severe manifestations of the disease, particularly in children. However, its effectiveness against pulmonary TB in adults remains variable, largely due to its limited ability to elicit a sustained antigen-specific TH1 immune response and to generate long-lived tissue-resident memory T cells (TRM) within the lungs. Consequently, innovative strategies that address these immunological shortcomings are needed to enhance BCG immunogenicity and efficacy against pulmonary TB. Recent studies on intravenous (IV)-BCG have emerged as a promising alternative, achieving near-sterilizing immunity in preclinical models such as nonhuman primates by strengthening pulmonary defenses against Mycobacterium tuberculosis (Mtb). This review examines how IV-BCG enhances BCG efficacy through a synergistic network of immunological factors, including trained immunity, effector TH1 cells, lung TRM, inducible bronchus-associated lymphoid tissue (iBALT), and antibody responses. Systemic delivery of IV-BCG induces durable trained immunity, primes robust TH1 and TRM responses in the lungs, may foster iBALT formation for localized protection, and enhances antibody production to reinforce humoral defenses. Drawing on data from preclinical studies, this review highlights how these components interconnect to sustain long-lasting pulmonary protection and offers insights into optimizing BCG-based TB vaccines.Keywords: Tuberculosis, Intravenous BCG, Trained immunity, TRM, iBALT, Antibody responses Introduction Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), remains a persistent global health crisis, with an estimated 10.8 million new cases and 1.25 million deaths in 2023, underscoring the urgent need for effective preventive measures [1]. The Bacillus Calmette-Guérin (BCG) vaccine, introduced in 1921, is the only licensed TB vaccine and has been highly effective in preventing severe forms of childhood TB, such as meningitis and disseminated disease [2]. Despite this success, its efficacy against pulmonary TB in adolescents and adults, the primary drivers of Mtb transmission, remains highly variable, ranging from no measurable protection to up to 80% across different populations and settings [3, 4]. This limited efficacy underscores the fundamental immunological limitations of the intradermal (ID) BCG vaccine. Because current ID-BCG vaccines are localized, they do not consistently elicit long-lasting antigen-specific T-helper 1 (TH1) responses, generate durable tissue-resident memory T cells (TRM) in the lungs, and mount robust antibody-mediated immunity [5–7]. Because pulmonary TB prevention requires rapid on-site effector responses and durable system-wide memory, novel strategies are needed to overcome these limitations. Intravenous (IV) BCG delivery has been identified as an appealing next-generation platform over the past few years. High-dose IV-BCG immunization can trigger nearly sterilizing immunity toward Mtb and boost the protection of the lungs dramatically compared with the ID delivery method, as suggested by preclinical studies within non-human primate (NHP) models [8–11]. Unlike ID administration, which largely confines immunological processes to local draining lymph nodes [12], IV delivery facilitates systemic immune responses to the vaccine. This unique route enables direct access to the bone marrow to induce trained immunity and seeds the lung parenchyma with high frequencies of effector cells, thereby establishing a multi-layered defense system that conventional routes fail to achieve [8, 13]. According to mechanistic studies, IV-BCG strengthens the innate and adaptive arms of host defense by inducing trained immunity, increasing antibody production, and activating dendritic cells (DCs) to prime strong TH1 and TRM responses in the lungs. Therefore, this review focuses on the immunological mechanisms by which IV-BCG enhances vaccine efficacy, with particular emphasis on the interplay between antigen-presenting cells, effector TH1 cells, lung-resident TRM populations, antibody function, and trained immunity. By integrating findings from recent preclinical studies, we aim to provide insights into how IV-BCG can serve as a foundation for developing optimized BCG-based vaccines capable of providing durable protection against pulmonary TB. BCG vaccination routes The protective efficacy of BCG depends significantly on the route of administration. While ID administration is currently the only approved route, the emerging mucosal and IV routes of administration produce different immune responses. Figure 1 illustrates the distinct outcomes resulting from different BCG administration routes. Distinct immunological outcomes following intradermal, mucosal, and intravenous BCG. The protective efficacy of BCG is highly dependent on the route of administration. Differences in antigen uptake, DC priming, mucosal seeding of TRM, antibody induction, iBALT formation, and trained innate immunity underlie the divergent outcomes of intradermal, mucosal, and intravenous BCG. Arrows indicate directionality of trafficking or signaling; green ticks denote advantages, and red crosses denote limitations. (a) Intradermal BCG. The conventional intradermal route enables antigen uptake by skin-resident DCs and subsequent priming of multifunctional TH1 cells in the draining lymph nodes. This generates systemic TH1-biased immunity but confers minimal induction of lung-localized responses. Consequently, intradermal BCG elicits only low levels of mucosal antibodies, induces few TRM in the respiratory tract, and fails to promote iBALT formation. (b) Mucosal BCG. Direct deposition in the respiratory tract promotes antigen uptake by lung-resident DCs, leading to TRM formation in the airway, TFH–dependent germinal center activity, and mucosal IgA secretion. Mucosal BCG also promotes iBALT formation, which sustains local immune responses through germinal centers and HEVs. In addition, mucosal delivery induces trained immunity via metabolic reprogramming of myeloid cells, including enhanced mitochondrial activity and TCA cycle flux, thereby augmenting innate antimicrobial function. Preclinical and early clinical studies demonstrate strong mucosal protection; however, systemic immunity remains limited, specialized delivery devices are required, and no licensed mucosal BCG product currently exists. (c) Intravenous BCG. Systemic administration results in broad dissemination of BCG to multiple lymphoid and non-lymphoid organs, driving robust DC maturation and systemic epigenetic training of innate immunity. This route elicits potent multifunctional T-cell responses, including cytotoxic CD8⁺ T cells, and establishes durable lung TRM populations with strong effector function. Intravenous BCG further promotes the generation of high-avidity antibodies across multiple isotypes (IgA, IgM, and IgG), thereby enhancing opsonization and bacterial clearance. Notably, intravenous vaccination has achieved sterilizing immunity in non-human primates, mediated by long-lived TRM and protective antibody responses. Despite its remarkable preclinical success, safety concerns and procedural complexity currently preclude its direct translation to humans, highlighting the need for innovative approaches that can capture the protective features of intravenous BCG while ensuring feasibility and safety. BCG, Bacillus Calmette-Guérin; DC, dendritic cell; TH1, T helper 1 cell; TFH, T follicular helper cell; TRM, tissue-resident memory T cell; HEV, high endothelial venule; iBALT, inducible bronchus-associated lymphoid tissue; IgA, immunoglobulin A; TCA, tricarboxylic acid ID-BCG vaccination: established but incomplete protection ID-BCG is currently the only approved vaccination route, administered to approximately 120 million newborns annually [1]. ID-BCG administration protects children against disseminated TB and meningitis by inducing systemic T cell responses, particularly IFN-γ-producing TH1 cells [14]. ID-BCG vaccination generates circulating effector T cells and central memory T cells, but these cells are rarely located within the lung parenchyma [7]. Consistent with this, an intravascular staining study in mice demonstrated that more than 95% of CD4+ T cells isolated from lungs after ID-BCG vaccination resided within the blood vessels, with only a small fraction present in the parenchyma. This suggests minimal influx of protective T cells into the tissues [15]. Furthermore, ID-BCG has been reported to weakly activate alveolar macrophages and airway-resident DCs, which are essential surveillance cells for early mucosal defense [15, 16]. This deficiency also delays T cell recruitment, impairs granuloma formation, and suboptimal early bacterial control after Mtb infection [17]. Consequently, ID-BCG provides variable and suboptimal protection against adult pulmonary TB, and its efficacy can be minimal depending on geographic and epidemiological factors [18, 19]. Another limitation is the insufficient establishment of immune surveillance in the respiratory mucosa, which constitutes the primary site of Mtb entry and replication. Recent data further indicate that high-dose IV-BCG profoundly enhances immune signaling within the airways, with upregulation of IFN-γ, TNF, IL-17, and CXCL9/10 in the bronchoalveolar compartment, alongside increased myeloid–lymphoid crosstalk [10]. This suggests that IV-BCG not only seeds protective T cells but also reprograms the airway microenvironment into a highly activated immune niche, reinforcing its superior protective efficacy. In addition, IV-BCG sustains germinal center reactions within secondary lymphoid organs, leading to the formation of long-lived plasma cells and memory B cells that secrete high-affinity IgG antibodies [43]. IV-BCG may also promote tertiary lymphoid structures such as iBALT, although this possibility remains speculative and requires further validation [8, 44, 45]. Beyond adaptive responses, IV-BCG imprints durable trained innate immunity. By disseminating to the bone marrow, BCG directly educates hematopoietic stem and progenitor cells, leading to long-term epigenetic and transcriptional reprogramming that biases their progeny monocytes and macrophages toward heightened cytokine responsiveness [13]. These stem cell-level changes, together with classical histone modifications such as H3K4me3 at inflammatory loci [28], provide a mechanistic explanation for the persistence of trained immunity months to years after vaccination. Importantly, this mechanism not only enhances Mtb control but also confers heterologous protection against unrelated pathogens through a process recently defined as “integrated organ immunity” in which antigen-specific CD4+ TH1 cells deliver IFN-γ feedback to lung myeloid and epithelial cells, imprinting prolonged innate antiviral resistance via MyD88-dependent interferon-stimulated gene activation [46]. Despite these advantages, IV-BCG faces significant challenges for clinical translation in its current form. High-doses of live bacteria administered systemically can raise serious safety concerns, including spleen hypertrophy, systemic inflammation, and disseminated BCGosis, especially in immunocompromised hosts [8, 47, 48]. Moreover, the use of IV-BCG administration for neonatal and infant subjects is not feasible. Variability among species also complicates interpretation. While NHP studies suggest near-complete protection, findings in mouse models are variable and the appropriate human dosage remains unknown [8, 49]. Compounding this uncertainty, certain high-dose regimens have been observed to overstimulate the immune system, leading to tolerance or adverse pathology [10]. Together, these issues highlight key limitations to the safe and effective clinical application of IV-BCG. For these reasons, IV-BCG should be regarded primarily as a biological benchmark. By uncovering the immune correlates of near-complete protection, massive TRM accumulation, durable germinal center activity, airway-specific immune activation, and long-lived trained immunity, IV-BCG provides a blueprint for rational vaccine design. Current research is focused on IV-mimetic platforms, such as recombinant vectors, liposomal or nanoparticle formulations, and heterologous prime–boost strategies, that aim to recapitulate the immunological benefits of IV-BCG while improving safety, scalability, and regulatory feasibility [50–52]. Combinatorial approaches that integrate ID priming, mucosal boosting, and IV-mimetic platforms may ultimately define the next generation of BCG vaccination strategies. Mucosal BCG vaccination: enhancement of lung-specific immunity The conventional ID-BCG vaccination has limitations in establishing robust mucosal immunity. To overcome this, various mucosal administration routes, such as intranasal, intratracheal, and aerosol, are being actively studied as alternatives. Mucosal vaccines directly target the respiratory tract and effectively enhance local lung immunity. In fact, studies in mouse and NHP models have shown that mucosal administration exhibits superior protective effects compared to ID vaccination, reducing the bacterial burden in the lungs by approximately 1.1–1.3 log10 CFU [7, 20, 21]. Unlike ID-BCG, mucosal vaccination induces systemic immunity and establishes a multilayered, localized protective barrier in the lungs. One of its key features is the formation of TRM, the first to respond when infection occurs again, enabling rapid on-site immune activation to suppress bacterial proliferation [7]. TRM have been reported to cooperate with CD4⁺ T cells that produce IL-17 to promote rapid neutrophil influx and strengthen the airway epithelial barrier, effectively suppressing the spread of pathogens in the early infection stage [22–25]. Furthermore, mucosal BCG administration promotes the generation of inducible bronchus-associated lymphoid tissue (iBALT), in which lymphocytes present antigens and are activated directly at the site of infection without going through lymph nodes (LNs), rapidly mobilizing effector T cells while also promoting mucosal IgA formation, effectively blocking the initial invasion of pathogens. Previous studies of oral BCG have also identified mucosal IgA and lung-resident lymphocytes as important protective factors [26, 27]. The rapid adaptive immune response is further enhanced by the trained immunity induced by mucosal BCG. Compared to ID-BCG vaccination, mucosal BCG induces a more robust functional reprogramming of innate immune cells, enhancing cytokine responsiveness and strengthening the link between innate and adaptive immunity [28]. Separately, recombinant strains such as rBCG-PPE27, exhibit a broader range of bacterial defenses than conventional BCG by altering alveolar macrophage metabolism through the mTORC2/HK1 pathway [29]. Mucosal BCG establishes a distinct surveillance system within the lungs, centered on TRM, iBALT, and IgA, which can function complementarily with ID-BCG, which focuses on systemic immunity. Therefore, a prime-boost strategy, which induces primary immunity through ID-BCG vaccination and then enhances it through the mucosal route, is an immunologically sound approach [8, 30, 31]. Nevertheless, there are numerous hurdles to overcome before clinical application. Major safety concerns, particularly in infants and immunocompromised patients, include the risk of aspiration, local inflammation, and inconsistent delivery doses [32]. Furthermore, the establishment of standardized delivery devices and quality control and regulatory systems is essential [33]. Current clinical trials still lack data on long-term safety and immune sustainability [34]. Therefore, applying mucosal BCG vaccination to clinical and public-health settings will require detailed translational studies and rigorous safety verification. IV-BCG vaccination: the standard for bactericidal protection Due to the limitations of ID- and mucosal BCG vaccinations, IV-BCG administration has attracted attention as the most innovative progress in TB vaccine research (Table 1). In NHPs, a single IV dose of BCG achieved an unprecedented level of protection. Specifically, in the landmark study by Darrah et al., 9 out of 10 macaques were highly protected following low-dose aerosol challenge with virulent Mtb (Erdman strain, ~ 10 CFU) administered 6 months post-vaccination. Most notably, 6 of these 10 animals achieved “sterilizing immunity,” defined as the complete absence of detectable CFU in all examined tissues—including individual lung lobes, thoracic lymph nodes, spleen, and liver [8]. This outcome, characterized by systemic bacterial clearance in the majority of subjects, is substantially greater than that of ID- or mucosal BCG administration [8, 35]. This efficacy results from systemic transmission of live BCG, enabling dissemination to the lung, spleen, liver, and bone marrow, and creating multilayer immune defenses across compartments [8, 29]. IV-BCG delivers universal and prolonged antigen availability, resulting in the elicitation of DC activation and robust TH1 differentiation [12]. As a result, multiple multifunctional CD4+ and CD8+ T cells are elicited and an antigen-specific TRM pool is formed within the parenchyma of the lung, enabling brisk recall responses upon re-exposure to Mtb [8]. Table 1Summary of IV-BCG examples and major mode of action against Mtb infectionStudiesKey FindingsDetailed Mode of ActionOutcomesRef.Mice(C57BL/6)IV-BCG vaccination induces rapid and robust activation of splenic APC, leading to systemic TH1-skewed T cell responses- Antigen delivery to the spleen- Activation of splenic DC and macrophage markers (MHC-II, CD80, CD86)- Cytokine production (IL-6, IL-10, IFN-g, TNF-α, IL-12)- Robust Ag-specific CD4+ T cell activation in secondary lymphoid organs- Rapid systemic immune activation- Strong TH1 responses- Efficient antigen presentation in the spleen[12]Mice(C57BL/6)IV-BCG vaccination confers protection via epigenetically programmed trained immunity, bypassing adaptive pathways- Transcriptional reprogramming of HSCs and MPPs, favoring myelopoiesis over lymphopoiesis- Epigenetic modifications (H3K4me3, H3K27ac)- Elevated cytokine expression (IFN-g, IL-1β, TNF-α) in macrophages- Significant reduction in Mtb load- Epigenetic reprogramming- Enhanced innate immunity and long-lasting effect[13]Mice(Diversity outbred)IV-BCG moderately improves survival after Mtb challenge in genetically diverse mice- Dissemination of BCG to multiple organs (lungs, spleen, liver, bone marrow)- Evidence highlighting the importance of vaccination route in protective efficacy[31]Mice(C57BL/6)IV-BCG vaccination induces broader and stronger IFN-γ responses against Ag85 and PE/PPE antigens than SC route- Strong IFN-γ responses in splenocytes- Enhanced recognition of multiple Mtb antigens, including Ag85A/B, PE/PPE family, TB10.4, and Esx-1- Broader and more robust T cell response[36]Mice (BALB/c)IV-BCG vaccination resulted in systemic dissemination of BCG and induced higher anti-BCG antibody titers than other delivery routes- Systemic dissemination via bloodstream- Strong humoral immune activation- Histopathologic inflammation in spleen and liver- Recognition of multiple BCG antigens (notably 65 kDa protein)- IV-BCG-elicited antibody responses of greatest magnitude among all vaccination routes- Systemic organ involvement- Broader antigen exposure and immune priming[37]Guinea pigsIV administration of killed BCG induces granulomatous lesions in tuberculin-sensitized guinea pigs- Delayed-type hypersensitivity reaction- Granuloma formation in lungs- Transient hepatic inflammation- Reduced inflammatory responses induced by viable BCG compared with killed preparations- Self-limiting lesion formation with resolution by 4 weeks- Evidence underscoring the risks of IV-BCG in sensitized subjects[38]Rhesus macaquesIV-BCG provides robust protection; 9/10 animals protected, 6 with no detectable infection- Substantially increased antigen-responsive CD4⁺ and CD8⁺ T cell responses in blood, spleen, BAL, and lung-draining lymph nodes- High-frequency antigen-responsive T cells distribution throughout lung parenchymal tissues contributing to enhanced protection- Robust protection against Mtb challenge- Significant reductions in detectable infection and disease pathology compared to other routes of BCG administration[8]Rhesus macaquesIV-BCG vaccination protected both SIV-infected and SIV-naive macaques from Mtb challenge- Induced robust airway CD4⁺ T cell influx- CD4⁺ T cells produced IFN-γ, TNF-α, and IL-2- Elevated plasma and airway antibody titers (specific isotypes not specified)- Demonstrated protective immunity even in immunocompromised (SIV-infected) hosts- Supported IV-BCG as a viable TB vaccine route in vulnerable populations[9]Rhesus macaquesHigh-dose IV-BCG sustains airway immune activation by recruiting polyfunctional T cells and macrophages, priming the lung mucosa for rapid and coordinated response to Mtb- Recruitment of polyfunctional CD4⁺ T cells and macrophages to the airways- Basal activation of alveolar macrophages with IFN and TNF-α signaling- Robust TH1/TH17 transcriptional responses upon antigen stimulation- Sustained immune activation in the airways- Primed airway environment for rapid Mtb clearance- Potential for improved vaccine strategies targeting mucosal immunity[10]Rhesus macaquesIV-BCG-mediated protection against Mtb requires both adaptive CD4⁺ T cells and innate CD8α⁺ lymphocytes, as depletion of either abrogates protective efficacy- Essential role of CD4⁺ T cells in controlling Mtb infection following IV-BCG vaccination- Protective contribution of CD8α⁺ lymphocytes, particularly innate subsets, through cytokine production and cytotoxic functions- Increased Mtb burden and dissemination following depletion of CD4⁺ T cells or CD8α⁺ lymphocytes, indicating loss of protection- Dominant protective role of innate CD8α⁺ lymphocytes over adaptive CD8αβ⁺ T cells[11]Rhesus macaquesIV-BCG vaccination induces trained immunity characterized by enhanced innate cytokine production and increased H3K27 acetylation in monocytes- Epigenetic reprogramming of monocytes mkared by H3K27ac, enhancing cytokine production upon stimulation- Robust trained immunity in monocytes[28]Rhesus macaquesIV-BCG induces robust airway-resident CD4⁺ T cells and NK cell responses together with Fc effector-functional mycobacteria-specific antibodies- Polyfunctional cytokine production (IFN-γ, TNF-α, IL-17) by airway-resident CD4+ T cells- Dose-dependent induction of mycobacteria-specific antibody responses in plasma and BAL fluid- Antibody-mediated complement activation and NK cell engagement as functional immune signatures associated with protection- Complete protection (sterile immunity) in several macaques- Airway, not blood, immune responses correlated with protection- Identification of humoral immune correlates of protection, highlighting the potential of antibody-based biomarkers to predict vaccine efficacy[35]Rhesus macaquesA distinct interferon-driven blood transcriptional module induced within 2 days of IV-BCG vaccination predicts long-term protection, offering early biomarkers of vaccine efficacy- Induction of module 1 expression (type I interferon and RIG-I-like receptor signaling pathways) at day 2- Early blood transcriptional responses predict protective efficacy (AUROC ≥ 0.91)- Strong correlation with reduced lung bacterial burden- Lower granuloma counts and lung pathology[39]Rhesus macaquesIV-BCG vaccination in rhesus macaques elicits robust antigen-specific IgM responses in both plasma and BAL fluid- High level induction of antigen-specific IgM, IgG, and IgA antibodies, particularly in the lungs- Functional activity of IgM antibodies, including enhanced Fc receptor binding and promotion of phagocytosis- Robust lung-compartmentalized antibody responses- Association of elevated IgM responses with enhanced protection against Mtb infection[40]Cynomolgus macaquesIV-BCG vaccination in non-human primates induces significantly higher titers of Mtb-specific IgG, IgA, and IgM in serum- Robust humoral responses with elevated levels of high-avidity IgG antibodies- Superior opsonizing capacity of IV-BCG-elicited antibodies enhancing phagocytosis of Mtb- Superior humoral immune responses with high-avidity, functionally potent antibodies[36]Rhesus macaquesγδ T cells induced by IV/aerosol BCG mediate protection against Mtb, independent of classical T cells- Systemic expansion of γδ T cells (especially Vγ9Vδ2)- γδ T cells produce IFN-γ and TNF-α, contributing to early protection- Reduced Mtb burden and lung inflammation- Novel correlate beyond classical adaptive responses[41]Rhesus macaquesNetwork modeling reveals key immune interactions and predicts effects of immune perturbations after IV-BCG- Markov field-based integration of systems serology, cytokines, and cytometry- Identification of key immune interactions contributing to vaccine efficacy- Prediction and experimental validation of immune perturbation effects on vaccine-induced protection- Identification of key immune interactions by Markov models- Experimentally confirmed immune network perturbations (e.g., B cell depletion) without loss of protective efficacy[42]APC antigen-presenting cell, HSC hematopoietic stem cell, MPP multipotent progenitor, DC dendritic cell, MHC-II major histocompatibility complex class II, CD cluster of differentiation, BAL bronchoalveolar lavage, γδ T cell gamma delta T cell, TFH T follicular helper cell TH1 T helper 1 cell, NK natural killer, TH17 T helper 17 cell, XCR1 chemokine receptor XCR1, SIV simian immunodeficiency virus, SC subcutaneous, TB tuberculosis, cDC1 conventional dendritic cell type 1, Ig immunoglobulin Summary of IV-BCG examples and major mode of action against Mtb infection Mice (C57BL/6) Mice (C57BL/6) - Transcriptional reprogramming of HSCs and MPPs, favoring myelopoiesis over lymphopoiesis - Epigenetic modifications (H3K4me3, H3K27ac) - Elevated cytokine expression (IFN-g, IL-1β, TNF-α) in macrophages - Significant reduction in Mtb load - Epigenetic reprogramming - Enhanced innate immunity and long-lasting effect Mice (Diversity outbred) Mice (C57BL/6) - Strong IFN-γ responses in splenocytes - Enhanced recognition of multiple Mtb antigens, including Ag85A/B, PE/PPE family, TB10.4, and Esx-1 - Systemic dissemination via bloodstream - Strong humoral immune activation - Histopathologic inflammation in spleen and liver - Recognition of multiple BCG antigens (notably 65 kDa protein) - IV-BCG-elicited antibody responses of greatest magnitude among all vaccination routes - Systemic organ involvement - Broader antigen exposure and immune priming - Delayed-type hypersensitivity reaction - Granuloma formation in lungs - Transient hepatic inflammation - Reduced inflammatory responses induced by viable BCG compared with killed preparations - Self-limiting lesion formation with resolution by 4 weeks - Evidence underscoring the risks of IV-BCG in sensitized subjects - Substantially increased antigen-responsive CD4⁺ and CD8⁺ T cell responses in blood, spleen, BAL, and lung-draining lymph nodes - High-frequency antigen-responsive T cells distribution throughout lung parenchymal tissues contributing to enhanced protection - Robust protection against Mtb challenge - Significant reductions in detectable infection and disease pathology compared to other routes of BCG administration - Induced robust airway CD4⁺ T cell influx - CD4⁺ T cells produced IFN-γ, TNF-α, and IL-2 - Elevated plasma and airway antibody titers (specific isotypes not specified) - Demonstrated protective immunity even in immunocompromised (SIV-infected) hosts - Supported IV-BCG as a viable TB vaccine route in vulnerable populations - Recruitment of polyfunctional CD4⁺ T cells and macrophages to the airways - Basal activation of alveolar macrophages with IFN and TNF-α signaling - Robust TH1/TH17 transcriptional responses upon antigen stimulation - Sustained immune activation in the airways - Primed airway environment for rapid Mtb clearance - Potential for improved vaccine strategies targeting mucosal immunity - Essential role of CD4⁺ T cells in controlling Mtb infection following IV-BCG vaccination - Protective contribution of CD8α⁺ lymphocytes, particularly innate subsets, through cytokine production and cytotoxic functions - Increased Mtb burden and dissemination following depletion of CD4⁺ T cells or CD8α⁺ lymphocytes, indicating loss of protection - Dominant protective role of innate CD8α⁺ lymphocytes over adaptive CD8αβ⁺ T cells - Polyfunctional cytokine production (IFN-γ, TNF-α, IL-17) by airway-resident CD4+ T cells - Dose-dependent induction of mycobacteria-specific antibody responses in plasma and BAL fluid - Antibody-mediated complement activation and NK cell engagement as functional immune signatures associated with protection - Complete protection (sterile immunity) in several macaques - Airway, not blood, immune responses correlated with protection - Identification of humoral immune correlates of protection, highlighting the potential of antibody-based biomarkers to predict vaccine efficacy - High level induction of antigen-specific IgM, IgG, and IgA antibodies, particularly in the lungs - Functional activity of IgM antibodies, including enhanced Fc receptor binding and promotion of phagocytosis - Robust lung-compartmentalized antibody responses - Association of elevated IgM responses with enhanced protection against Mtb infection - Robust humoral responses with elevated levels of high-avidity IgG antibodies - Superior opsonizing capacity of IV-BCG-elicited antibodies enhancing phagocytosis of Mtb - Markov field-based integration of systems serology, cytokines, and cytometry - Identification of key immune interactions contributing to vaccine efficacy - Prediction and experimental validation of immune perturbation effects on vaccine-induced protection - Identification of key immune interactions by Markov models - Experimentally confirmed immune network perturbations (e.g., B cell depletion) without loss of protective efficacy APC antigen-presenting cell, HSC hematopoietic stem cell, MPP multipotent progenitor, DC dendritic cell, MHC-II major histocompatibility complex class II, CD cluster of differentiation, BAL bronchoalveolar lavage, γδ T cell gamma delta T cell, TFH T follicular helper cell TH1 T helper 1 cell, NK natural killer, TH17 T helper 17 cell, XCR1 chemokine receptor XCR1, SIV simian immunodeficiency virus, SC subcutaneous, TB tuberculosis, cDC1 conventional dendritic cell type 1, Ig immunoglobulin Key immunological components of IV-BCG vaccination Continuous research has focused on identifying the key immunological components that influence TB vaccine efficacy. Notably, several strategies leveraging these factors have demonstrated enhanced BCG vaccine performance when delivered via IV-BCG administration. Furthermore, distinct features of innate and adaptive immune responses that correlate with protective outcomes hold promise as potential biomarkers for vaccine efficacy (Fig. 2; Table 2). Intravenous BCG orchestrates multilayered immune programs that drive broad protection. IV-BCG vaccination activates innate, adaptive and tissue-resident compartments in concert, providing durable protection against Mtb and even heterologous pathogens. The schematic highlights interconnected pathways ranging from bone marrow reprogramming to tertiary lymphoid organization. Solid arrows indicate established mechanisms, whereas dashed arrows and question marks mark incompletely defined links. (1) Trained immunity in HSPCs. IV-BCG reaches the bone marrow and imprints HSPCs with histone modifications (H3K4me1/3, H3K27ac). This biases differentiation toward monocytes and DCs with elevated MHC-I/II, CD11c, CD80, and CD86, accompanied by augmented cytokine release such as IFN-α/β, and IL-12. Additional activation markers, including CD40 and XCR1, further reflect enhanced antigen-presenting capacity. (2) Multifunctional T cells. Antigen-loaded DCs present to CD4⁺ and CD8⁺ T cells through MHC and CD40–CD40L engagement, promoting IL-2–driven expansion of polyfunctional subsets that secrete IFN-g, TNF-α and IL-17 simultaneously, enhancing effector potency. (3) Tissue-resident memory T cells. Effector T cells traffic to the lung in response to TGF-β and IL-15 secreted by DCs, where they establish TRM characterized by the expression of CD69, CD103 and VLA-1. These cells persist long term and rapidly secrete IFN-g, IL-2, TNF-α and granzyme B upon pathogen encounter, providing immediate frontline protection. (4) Germinal center activity. TFH cells interact with B cells via CD40L and cytokines (IL-4, IL-6, and IL-21), strengthening germinal center reactions, broadening B cell repertoires and generating durable memory and plasma cell populations. (5) Antibody diversification. Plasma cells secrete IgM, IgA and IgG with complementary roles: IgM mediates avid binding and complement activation, IgA protects mucosal surfaces by neutralizing bacteria, and IgG supports opsonization and Fc receptor–mediated clearance. The combined antibody repertoire expands effector mechanisms and synergizes with cellular immunity. (6) Potential iBALT formation. IV-BCG may accelerate the formation of iBALT containing HEVs, B cell follicles and FDCs. These tertiary lymphoid structures could sustain antigen presentation and recall responses, though their contribution to protection remains to be fully defined. (7) Reinforced macrophage activity. Trained monocytes and macrophages infiltrate the lung and express elevated MHC-II and CD11b, reflecting enhanced antigen presentation and phagocytic capacity. Together with cytokines such as IFN-γ, IL-17 and TNF-α from T cells, these myeloid cells exhibit increased phagolysosomal fusion and antimicrobial effector functions that contribute to bacterial clearance. Collectively, IV-BCG coordinates epigenetically trained innate and dendritic cell programs with the generation of multifunctional T cells, durable TRM, expanded antibody repertoires, and potential iBALT formation, thereby achieving sterilizing immunity in non-human primates and underscoring the promise—as well as the challenges—of translation to humans. DC, dendritic cell; HSPCs, hematopoietic stem and progenitor cells; TRM, tissue-resident memory T cell; TFH, T follicular helper cell; GC, germinal center; iBALT, inducible bronchus-associated lymphoid tissue; HEV, high endothelial venule; FDC, follicular dendritic cell; Ig, immunoglobulin Table 2Roles of key immunological factors in vaccine efficacy and TB protectionFactorGeneral Role in Vaccine EfficacySpecialized Role Against MtbRef.Trained ImmunityProvides innate immune memory through epigenetic and metabolic reprogramming of monocytes, macrophages, and DCs, enhancing nonspecific and broad protection against diverse pathogens.Post-IV-BCG, trained immunity strengthens macrophage and DC responses against Mtb by promoting glycolytic reprogramming, Akt-mTOR-HIF1α signaling, and epigenetic modifications, leading to enhanced antimycobacterial activity.[13, 28, 53–60]DCsAct as professional APC that bridge innate and adaptive immunity by sensing antigens, secreting cytokines, and directing T cell differentiation. Maintain immune homeostasis while rapidly initiating protective adaptive responses.DCs sense Mtb antigens and present them via MHC-II to drive CD4⁺ and CD8⁺ T cell priming. In IV-BCG vaccination, lung cDC1s are expanded and activated (CD86, CD40, XCR1, IL-12), enhancing cross-presentation and adaptive CD8⁺ T cell responses, leading to robust pulmonary immunity and reduced pathology.[12, 61–64]Antigen-Specific T CellsAdaptive immune backbone of vaccine efficacy; CD4⁺ and CD8⁺ T cells respond to antigen presentation, providing long-lasting, specific immunity and immunological memory.IV-BCG induces highly polyfunctional CD4⁺ and CD8⁺ T cells (producing IFN-γ, TNF-α, IL-2) enriched in lung parenchyma and lymphoid tissues. Their frequency and polyfunctionality correlate with reduced Mtb burden and protection, suggesting establishment of TRM-like populations.[8, 10, 12, 35]Effector TH1 CellsCentral effector subset of CD4⁺ T cells that secrete IFN-γ, IL-2, and TNF-α to orchestrate protective immunity. Serve as biomarkers of vaccine efficacy and correlate with pathogen control.In TB infection, TH1 cells are indispensable for protection; deficiency in IFN-γ leads to high susceptibility to mycobacterial disease. IV-BCG promotes strong TH1/TH17-polarized responses in airway and lung tissue, engaging cross-talk with myeloid cells.[65–71]TRM CellsProvide rapid, localized immune responses at barrier tissues (e.g., lung, mucosa) by remaining in situ after initial infection or vaccination. Defined by CD69⁺CD103⁺ phenotype and supported by cytokines such as TGF-β and IL-15.IV-BCG induces abundant TRM-like CD4⁺ and CD8⁺ T cells (> 80% in lung parenchyma), producing IFN-γ, IL-17, and TNF-α. These cells interact with alveolar macrophages, sustain iBALT structures, and provide near-sterilizing pulmonary immunity in NHPs, ensuring rapid lung-specific protection against Mtb.[7, 8, 35, 72–78]Antibody FunctionAntigen-specific antibodies (IgG, IgA, IgM) complement cellular immunity by enabling effector functions such as opsonization, complement activation, and Fc receptor–mediated responses. B cell–TFH cell interactions drive germinal center formation and antibody diversification.IV-BCG induces strong lung-compartmentalized IgG and IgA, while plasma and BAL IgM correlate with reduced Mtb burden. IgM monoclonal antibodies can directly limit bacterial survival. Antibodies reduce lung pathology, enhance DC uptake, support TRM and iBALT formation, and synergize with innate and adaptive immunity to contain Mtb.[9, 40, 43, 79–81]iBALT FormationActs as a TLS in the lung, providing localized hubs for immune coordination. Supports T cell priming, B cell maturation, antibody production, and integration of cellular and humoral immunity.IV-BCG may induce iBALT through IL-23–ILC3–IL-17–CXCL13 axis, TH1-derived IFN-γ/TNF-α, and DC activity. Within iBALT, TH1/TRM cells sustain cytokine output, B cells produce IgA/IgG, and trained DCs enhance antigen presentation. This localized immune hub promotes opsonization, macrophage activation, and containment of Mtb—though its role in human TB remains debated due to variability in granuloma/iBALT presence.[82–90]DC dendritic cell, APC antigen-presenting cell, MHC-II major histocompatibility complex class II, cDC1 conventional dendritic cell type 1, TRM tissue-resident memory T cell, iBALT inducible bronchus-associated lymphoid tissue, NHP non-human primate, Ig immunoglobulin, TFH T follicular helper cell, GC germinal center, TLS tertiary lymphoid structure, ILC3 group 3 innate lymphoid cell Roles of key immunological factors in vaccine efficacy and TB protection DC dendritic cell, APC antigen-presenting cell, MHC-II major histocompatibility complex class II, cDC1 conventional dendritic cell type 1, TRM tissue-resident memory T cell, iBALT inducible bronchus-associated lymphoid tissue, NHP non-human primate, Ig immunoglobulin, TFH T follicular helper cell, GC germinal center, TLS tertiary lymphoid structure, ILC3 group 3 innate lymphoid cell Trained immunity: innate amplification Trained immunity, also referred to as innate immune memory, is a consequence of epigenetic and metabolic reprogramming events in innate immune cells such as monocytes, macrophages, and DCs [53–55, 91]. Unlike adaptive immunity, which generates antigen-specific and long-lasting memory through B and T lymphocytes, trained immunity represents functional adaptations of myeloid cells and natural killer (NK) cells. These adaptations rely on transcriptional, metabolic, and epigenetic remodeling that heightens nonspecific responses against diverse pathogens [56–58, 92, 93]. Mechanistically, IV-BCG promotes epigenetic modifications (e.g., H3K4me3 and H3K27ac) and metabolic shifts (e.g., glycolysis) in macrophages and DCs, thereby enhancing antimycobacterial protection in both murine and NHP models [13, 28]. Xu et al. demonstrated that BCG-induced training depends on the Akt-mTOR-HIF1α axis, glycolytic activation, and NOD-like receptor signaling, with differences in linoleic acid metabolism modulating the degree of trained protection against TB [59]. Similarly, Minute et al. reported that heat-killed Mtb induces trained immunity in human monocytes via epigenetic remodeling in a Syk/HIF-1α-dependent manner [60]. Systemic IV-BCG-induced trained immunity was reported to provide T- and B-lymphocyte-independent protection and broad, nonspecific resistance to infections. DCs can undergo memory-like reprogramming under specific immunization strategies. For example, in a murine model, DCs isolated from immunized hosts displayed enhanced transcriptional activation of interferon and immune signaling pathways, along with sustained cytokine responses upon re-exposure to the same pathogen [94]. Notably, this prolonged response was abolished when histone modifications were inhibited, highlighting the critical role of epigenetic remodeling in establishing a memory-like state in DCs. These reprogrammed DCs not only produce innate cytokines more effectively but also markedly enhance T cell priming, positioning DC epigenetic reprogramming as a potential bridge between trained and adaptive immunity. Moreover, this epigenetic and metabolic reprogramming of innate immune cells also enhances defense against secondary infections including C. albicans, Brucella abortus, and virus [13, 57, 95–103]. In addition, BCG-induced trained immunity has also been applied as an immunotherapy for bladder cancer, underscoring its relevance beyond infectious diseases [104, 105]. Consequently, IV-BCG induced trained immunity may offer a promising avenue to improve the efficacy of the current BCG vaccine and to develop novel vaccines that integrate classical adaptive and innate immune memory. DC: The Initiating Link between innate and adaptive immunity DCs play a key role in balancing immunity and tolerance by bridging innate information to generate either protective or pathological adaptive immunity in many diseases [61, 106]. DCs constitute a distinct lineage of cell populations with the capacity to seed tissues and maintain immune homeostasis in the steady state, while rapidly responding to local insults and initiating as well as directing innate and adaptive immunity through communication with other immune cells [62]. In addition, DCs are crucial for sensing antigens from Mtb and Mtb-infected cells, then secreting effector signals to drive the differentiation and polarization of T cells necessary to clear infection [107–110]. In the lung, tissue-resident DCs (cDC1s, cDC2s, and pDCs) serve as professional antigen-presenting cells (APC), capturing pathogens, migrating to draining LNs, and priming naïve CD4⁺ and CD8⁺ T cells [63]. Following priming, effector and memory T cells, including potential TRM, return to the lung, where local antigen presentation and cytokines, such as TGF-β and IL-15, support tissue retention and durable immunity [63]. Dendritic cells are pivotal in determining the efficacy of IV-BCG, acting as professional APCs that are more efficient than macrophages [12]. This correlates with increased expression of MHC-II molecules and their transcriptional regulator CIITA, underscoring route-dependent differences in the spatial and temporal dynamics of APC activation. Systemic IV-BCG-mediated lung immunity critically depends on cDC1s, which directly present antigen to naive CD4+ T cells [63, 111], and subsequently prime TH1, TH1-like T follicular helper (TFH), and regulatory T cells [112]. Additionally, cDC1s are highly efficient at antigen cross-presentation, activating CD8+ T cell through the secretion of IL-12 and type I IFN [39, 113–115]. IV-BCG increases pulmonary cDC1 numbers and upregulates activation markers, including CD80, CD86, CD40, and XCR1, while boosting IL-12 production, collectively promoting TH1 priming [64]. Therefore, IV-BCG elicits robust systemic and pulmonary T cell responses and confers substantial protection against Mtb challenge in part via trained DC-mediated reprogramming, with reduced lung pathology [8]. However, their precise role in TB remains uncertain, as direct human evidence is lacking and chronic Mtb exposure could potentially dampen such training effects. By integrating pathogen-derived signals, DCs appear poised to bridge innate sensing and adaptive immunity, but their role in human disease has yet to be fully defined. Multifunctional TH1 cells: the adaptive core Antigen-specific T cells, particularly effector TH1 cells, form the adaptive backbone of protection induced by IV-BCG. Through DC-mediated antigen presentation, these TH1 cells mount robust responses that are central to controlling Mtb infection [8, 12, 35]. CD4⁺ T cells serve as critical effector cells in the host immune response to Mtb, with the TH1 subset playing a pivotal role by secreting IFN-g, IL-2, and TNF-α to orchestrate protective immunity [65]. In TB vaccine research, reductions in Mtb burden in the lungs and spleens of murine models have strongly correlated with the frequency and proportion of multifunctional CD4⁺ T cells [66]. Consequently, the cytokine profiles of TH1 cells specific to Mtb antigens have been widely adopted as immunological biomarkers and investigated as predictors of protective efficacy in TB vaccine assessments [67–69]. In particular, IFN-g is indispensable for eliciting protective immunity, and its deficiency is associated with markedly increased susceptibility to mycobacterial infections [70, 71]. In NHPs, IV-BCG vaccination induced highly polyfunctional CD4⁺ and CD8⁺ T cell responses, characterized by IFN-g, IL-2, and TNF-α production, which were particularly enriched in lung parenchyma and lymphoid tissues [8, 10]. These airway-resident T cells displayed strong TH1/TH17 polarization and engaged in active cross-talk with airway myeloid cells, as indicated by ligand–receptor interactions [10]. Their differentiation was defined by transcription factors such as EGR2, NR4A3, IRF4, RPBJ, TBX21 (T-bet), BATF, and RORC, while genes including IL23R, IL21R, PIK3CG, and TJP2 were associated with long-lived effector states [10]. The frequency and functionality of these polyfunctional T cells strongly correlated with reduced Mtb burden after challenge, establishing them as key immune correlates of IV-BCG–mediated protection [35]. Collectively, these findings demonstrate that IV-BCG elicits broad and durable antigen-specific CD4⁺ and CD8⁺ T cell responses that disseminate throughout the lung parenchyma and confer remarkable protection against Mtb challenge [8]. Extensive localization of long-lived T cells suggests the potential establishment of TRM-like populations within the TH1 subset. Indeed, it has been found that IV-BCG has an increased transcriptional program characterized by tissue maintenance and durable effector status [10], and is also rich in intra-airway multifunctional and conducive CD4+ T cells. Thus, IV-BCG can promote TRM-like features in the lungs as well as induce systemic and pulmonary effector T cell responses, which are increasingly recognized as important correlations of protective immunity to TB. TRM: lung-specific guardians TRM play an instrumental role in local immune responses against a wide range of both viral and bacterial infections, rapidly responding to pathogenic insults through their memory of previously encountered pathogens [72, 73, 116, 117]. Phenotypically, TRM are most often defined as CD69+CD103+ and exhibit increased transcription of markers such as Itgae (CD103) in CD4+ T cells and Itga1 (VLA-1) in CD8+ T cells [7, 74]. Furthermore, specific TRM subsets producing IFN-γ or IL-17 are important in the control of Mtb in mice as well as in the human lung [75, 76]. IV-BCG in NHPs induced > 80% lung parenchyma–derived CD4⁺ and CD8⁺ T cells with TRM-like phenotypes, versus 16–35% after ID- or mucosal BCG. Antigen stimulation revealed IFN-g-producing CD4⁺ T cells across lung lobes and LNs, high expression of CD69 and CD103, indicating IV-BCG establishes abundant antigen-responsive TRM-like cells associated with superior protection [8]. DCs are the major cells that prime TRM by presenting antigens and secreting TGF-β and IL-15, thereby driving their migration to the lungs [77, 78]. After localizing adjacent to alveolar macrophages, TRM secrete IFN-g, IL-17, granzyme B, and TNF-α, which together suppress Mtb growth within days and achieve near-sterilizing immunity in NHPs. Notably, antigen-responsive T cells remain elevated in the lung parenchyma and bronchoalveolar lavage (BAL) for up to six months following IV-BCG vaccination [8, 35, 44, 118]. TRM are derived from TH1 cells, maintains antigen specificity, and sustains iBALT through cytokine production [82, 119]. TRM have been shown to provide rapid, localized control of Mtb in the lungs following IV-BCG, by integrating DC priming, TH1 support, iBALT synergy, and innate enhancement, to ensure rapid, lung-specific immunity critical for pulmonary protection [8, 35]. Antibody function: T cell-mediated humoral reinforcement Several studies have proposed IFN-g independent protective immune responses against TB [79, 120, 121]. Among these, antigen-specific antibody responses have emerged as promising correlates of protection [43, 79, 122–124]. Mechanistically, DCs activate TFH cells, which mature in germinal centers and drive B cell–mediated antibody production [125]. TFH cells can be repeatedly primed and are characterized primarily by their secretion of IL-21 [126]. These IL-21-producing CD4+ T cells also express BCL6, a transcriptional regulator, and the chemokine receptor CXCR5, both of which are crucial markers of TFH cells [126]. TFH cells further contribute to B cell differentiation and antibody maturation through the production of other cytokines such as IL-4 [126]. Antigen-specific B cells, in turn, orchestrate the positioning of TFH cells into lymphoid follicles. This establishes a B cell-TFH cell axis that supports germinal-center formation and promotes high-affinity IgG1 antibody responses, and contributes to effective control of Mtb [125–131]. Through this pathway, B cells differentiate into plasma cells that generate multiple antibody isotypes, thereby enabling diverse effector functions such as opsonization, complement activation, and Fc receptor-mediated responses [83, 132]. Once considered irrelevant in controlling an intracellular pathogen, antibodies are now recognized to reduce lung pathology in NHP models of IV-BCG [43], while murine aerosol BCG studies have linked anti-Ag85A IgG responses to reduced TB incidence [133]. Mucosal IgA complements TRM and iBALT formation by neutralizing Mtb locally [80], whereas trained macrophages enhance IgG-mediated efficacy [81]. IV-BCG vaccination in NHPs induced stronger antigen-specific humoral immunity than ID-BCG, characterized by robust lung-compartmentalized IgG and IgA responses that contribute to enhanced Mtb containment [9]. In addition, plasma and BAL IgM levels correlated with reduced bacterial burden, and an Mtb-specific IgM monoclonal antibody directly limited bacterial survival, highlighting a protective role for IgM in IV-BCG–induced immunity [40]. Together, these humoral responses integrate with cellular immunity to amplify DC uptake, support TRM development, and promote iBALT formation, collectively strengthening pulmonary containment of Mtb. iBALT formation: localized immune coordination iBALT represents a tertiary lymphoid structure (TLS) that emerges in the lung under conditions of infection or chronic inflammation. It is organized into discrete T cell and B cell compartments, often resembling follicular aggregates, and is accompanied by DCs that facilitate local antigen presentation [82, 84, 85]. Functionally, iBALT serves as an ectopic site where T and B lymphocytes interact, enabling the coordination of cell-mediated and humoral immune responses directly within the pulmonary tissue. Lung-derived IL-23 stimulates ILC3s to produce IL-17 and IL-22, of which IL-17 induces CXCL13 expression in stromal cells [86]. CXCL13 attracts CXCR5⁺ lymphocytes to the lung parenchyma, leading to the structured assembly of iBALT and promoting early immune containment of infection [86]. In parallel, IFN-γ and TNF-α secreted by TH1 cells initiate lymphocyte infiltration, and DC subsets such as follicular DCs enhance the organization of these aggregates [82, 85]. Once established, iBALT functions as a hub where multiple immune subsets cooperate. TRM provides sustained cytokine release, B cells differentiate into antibody-secreting plasma cells, and memory B cells persist to support long-term recall immunity [87, 88, 134, 135]. Consequently, the collective effect is improved antibody-mediated opsonization, enhanced cytokine-driven macrophage activation, and more effective pathogen uptake. A hallmark of functional TLSs, including iBALT, is the presence of high endothelial venules (HEVs). These PNAd⁺ vascular structures enable continuous recruitment of naïve T and B lymphocytes via CCR7–CCL21 signaling, thereby sustaining the immunological activity of iBALT [87]. Murine models of TB consistently demonstrate robust HEV⁺ iBALT formation that correlates with reduced bacterial loads [136]. By contrast, human post-mortem studies have reported variable or incomplete iBALT and HEV development, which may reflect differences in host immunity, bacterial strain diversity, or the immunosuppressive environment of advanced TB lesions [137]. In the context of IV-BCG, iBALT induction has not yet been directly demonstrated; nonetheless, the high pulmonary antigen burden and sustained TH1 activation observed with high-dose IV-BCG raise the hypothesis that this route could foster HEV⁺ iBALT [10, 44]. Such ectopic lymphoid niches could amplify protection by sustaining lymphocyte recruitment, promoting local antibody maturation, and integrating opsonization with macrophage effector functions [83, 89, 90]. It is important to distinguish the protective role of vaccine-induced iBALT from the pathological iBALT observed in chronic respiratory diseases [138]. In conditions such as chronic obstructive pulmonary disease and asthma, iBALT formation is often driven by persistent, dysregulated inflammation, leading to aberrant tissue remodeling, airflow obstruction, and tissue damage [139]. Conversely, in the context of IV-BCG vaccination, iBALT is considered a functional immune hub. Instead of driving chronic pathology, it facilitates the organized interaction of T cells, B cells, and APCs directly at the site of potential infection. This localized structure enables a rapid, on-site recall response that contains Mtb within granulomas before it can disseminate, thereby serving as a critical component of sterilizing immunity rather than a driver of disease [137]. Although some reports caution that iBALT may serve as a reservoir for mycobacteria under conditions of dysregulated inflammation [17, 140, 141], the prevailing evidence suggests that when appropriately induced, iBALT can act as a powerful adjunct to granuloma formation, strengthening pulmonary immunity and accelerating protective responses against Mtb. IV-BCG vaccine application in the context of underlying diseases Although relatively few studies have examined the efficacy of IV-BCG beyond TB, IV administration of BCG appears to broaden its protective capacity, exerting disease-modifying effects in cancer, infectious diseases, and metabolic diseases. BCG is well known to enhance antibacterial defenses through trained immunity, improving host resistance against unrelated bacterial pathogens [99]. It is plausible that IV delivery, by amplifying systemic antigen exposure and myeloid reprogramming, could further potentiate this broad-spectrum antibacterial effect, although direct experimental evidence remains scarce [10]. In lung cancer models, IV-BCG reduced tumor burden and improved survival through cDC1-dependent CD8⁺ T cell priming and NK cell-mediated immunity, while also synergizing with PD-L1 checkpoint blockade to overcome otherwise resistant tumor microenvironments [64]. In viral infection model, particularly SARS-CoV-2, IV-BCG lowered viral load, mitigated lung pathology, and prevented lymphopenia in hamsters by expanding TH1, TH17, cytotoxic T lymphocytes, regulatory T cells, and plasma cells, while reprogramming macrophages and limiting neutrophil-driven pathology, thereby integrating trained innate and adaptive responses. Moreover, in influenza A virus infection model, systemic IV-BCG conferred heterologous protection in mice by expanding CX3CR1hi effector memory CD4⁺ T cells, whose antigen-independent IFN-g production enhanced alveolar macrophage activity, thereby linking adaptive and innate memory [142]. Additionally, IV-BCG administration in obese, diabetic ob/ob mice alleviated nonalcoholic fatty liver disease by reducing hepatic lipid accumulation, suppressing lipogenic gene expression, and improving insulin sensitivity. Mechanistically, BCG mitigated ER stress and restored insulin signaling in hepatocytes, suggesting that IV-BCG can remodel metabolism and provide therapeutic benefit in obesity-associated fatty liver disease [143]. Collectively, BCG has been associated with heterologous protection against bacterial pathogens, cancers, metabolic disorders, and viral infections [96, 144–147]. While direct evidence for IV-BCG in these contexts remains limited, intravenous delivery—by amplifying systemic antigen exposure and driving myeloid reprogramming—may further potentiate these broad-spectrum effects [10]. Emerging data suggest that IV-BCG can reprogram immune and metabolic networks with potential benefits beyond TB. Conclusion and perspectives In this review, we summarized the synergistic immune interactions induced by IV-BCG vaccination. IV-BCG modifies the pulmonary protective effect of BCG by forming a synergistic immune network against Mtb. IV-BCG trains monocytes, and trained DCs initiate a chain reaction that activates effector TH1 cells and TRM in the lungs. TH1 and TRM cytokines can form a local immune hub, the iBALT. Antibodies induced by activated TFH cells, which opsonize Mtb and complement TRM and iBALT at the mucosal level, enhancing cellular immunity. This trained immunity enhances innate immunity and supports TRM maintenance, iBALT function, and antibody efficacy. IV-BCG achieves near-sterilizing protection over months of follow-up, substantially exceeding ID-BCG in the NHP model, but translation to humans still requires rigorous safety evaluation and dose optimization [8–11]. The synergistic effect relies on systemic administration of IV-BCG, allowing trained DCs to directly link adaptive, humoral, and innate responses in the lung, the primary battleground for Mtb. To translate the efficacy of IV-BCG to human vaccination, further studies are needed to ensure safety, optimize dose, and consider the heterogeneity of various populations. To this end, TLR agonists and other adjuvants that train DCs or induce iBALT may enhance TH1 and TRM responses [146–148]. Furthermore, co-administration of IV-BCG with Mtb-specific antigens may expand antigen-specific T cell diversity, overcoming strain-specific variability [149]. In addition, co-administration with existing anti-TB treatments may accelerate bacterial clearance in active TB [9]. However, the extent to which these immune cell-mediated mechanisms operate similarly in humans remains uncertain, as key features such as DC training efficacy, iBALT formation, and the generation and persistence of pulmonary TRM cells differ between animal and humans. While these strategies could be considered for IV-BCG application, they have currently only been demonstrated in non-human primate studies, emphasizing the need for further studies in the human setting. Taken together, IV-BCG vaccination is highly effective against Mtb infection and disease. It orchestrates a multi-layered immune program that integrates innate training, adaptive T cell responses, antibody activation, and localized iBALT formation through a systemic immune response. Although the safety concerns associated with systemic live bacterial administration currently limit the direct clinical application of IV-BCG, its ability to induce near-sterilizing immunity makes it an invaluable biological benchmark [8, 47]. By demonstrating that robust protection requires the synergistic activation of systemic trained immunity and lung-resident memory [13, 35], IV-BCG provides a clear rationale for future vaccine strategies. These insights are now guiding the design of safer alternatives, such as mucosal vaccines or heterologous prime-boost regimens, which aim to mimic the comprehensive immune landscape of IV-BCG without its associated risks [7, 31, 50]. Collectively, this coordinated immune environment supports durable and broad protection against Mtb, positioning IV-BCG as a critical reference point for next-generation TB vaccine development. While significant challenges remain before human application, preclinical studies highlight the promising potential of BCG to transform the prevention of TB. Acknowledgements MID (Medical Illustration & Design), as a member of the Medical Research Support Services of Yonsei University College of Medicine, providing excellent support with medical illustration. Author contribution S.C. and J.P. wrote the first draft of the manuscript. J.J.H. contributed to the organization and structure of the review and assisted in editing the final version. S.J.S. and J.M.L. conceived the project, contributed to writing, and thoroughly revised the manuscript. All authors read and approved the final version of the manuscript. Funding This work was supported by the Korea Research Institute of Bioscience and Biotechnology (KRIBB) Research Initiative Program (KGM4572532), by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare (RS-2025-02173063), and by a grant from Ministry of Food and Drug Safety (26202MFDS013) in 2026, South Korea. Data availability Not applicable for review articles. Declarations Ethics approval and consent to participate Not applicable. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Sangwon Choi and Jiyun Park contributed equally to this work. Contributor Information Sung Jae Shin, Email: sjshin@yuhs.ac. Ju Mi Lee, Email: jmlee@yuhs.ac. References Associated Data Data Availability Statement Not applicable for review articles.